Portuguese pharmaceutical company agreed to be a founding member of the Orepeutics Company for the Biotechnology Company (OTXL), which focuses on obtaining and restarting the development of promising drugs in clinical training “Archive “high diseases and provide a trading path.
The agreement with the Biotechnology Company will be accelerated Rare diseases As a founding member, bilateral You will play a major role in the selection, in the final stages of development and marketing program marketing, which will be announced in the coming months, according to reports in a statement.
This is one of OTXL partnerships with global biotechnology companies intended for rare diseases and pharmaceutical companies, as well as with companies specialized in clinical research and pharmaceutical manufacturing as well as artificial intelligence -based platform suppliers.
The goal of partnerships is to resume the development of promising treatments that were in the clinical trial stage, but were stopped by companies due to financial challenges and the market.
“Our goal in supporting this ambitious project is to make some of these treatments have been investigated again, i.e. in clinical trials, to have a great impact on patients, as well as a great value for those who invest in their development,” explained by Smitha Gagadish, responsible for the field of rare diseases in BIAL.
As a non -profit organization, OTXL intends to work with organizers, investors and others interested in changing the research model in rare diseases and serving patients and better families. Martin, Founder and CEO of OTXL.
More than 400 million people, half of them, in the world, are affected by rare diseases, which are mostly genetic, progressive and chronic diseases. There are currently more than 11,000 diseases that have been rare, of which 95 % do not suffer from treatment.
